Clearly much moren eeds to be done and studied to find the optimal cell source for each regeneration purposea nd tissue. Yetb yd efinition,m ultipotent SSCs capable of transdifferentiation into multiple phenotypes should be usable for most tissues. As said, SSCs from different sources may have ap referred niche and aprimary differentiation type, however,t his seems to be largely controlled by their environment. SSCs arer esident in adult tissues, but constitute only aminor part of the total cell numbers. For transplantation purposes such as etting makes prior isolation and enrichment necessary. When needed, sufficient cell numbers can be attained by further ex vivo culturing, however recent evidence has suggested that culturing may limit their regenerative potential (1, 2). SSC isolation protocols vary from functional to immunophenotypic with the former utilizing usuallyd ifferential adherence to cell culture materials or dye exclusions, whereas the latter selects cells based on their expression of cell surface molecules.
In this review we focus on the SSC types currently indicated for cardiac regenerationa nd the methods for their surgical application into the failing heart.
TISSUe PoolS oF SoMATIC STeM CellS
Various tissues have been identified to contain multipotent progenitorc ells (3). Adult stem cells with (trans)differentiation potential useful for cardiac regeneration have been reportedly isolated from heart, bone marrow,s keletal muscle, adipose tissue, and skin (4, 5, 6, 7, 8).
CARDIAC STeM CellS
Not longago cardiac muscle cells, like neurons, were considered an ultimately differentiated static population that had used up all mitotic potential. This view was challenged by Dr Anversa's group late last cen-
INTRoDUCTIoN
It has been long waited for that stem cell therapy redeemed the promises for tissue and organ regeneration. Recent advances have overcome the numerous ethical issues by limiting transplantation therapy to the patients'o wn stem or precursor cells or somatic stem cells (SSCs). Such multipotent cells, capable of differentiating several -y et limited -o ther cell types, can be isolated from variousorgans in the adult body,a nd may aid to regenerate the failing heart ( Fig. 1) .P otential harvest sites include bone marrow, skeletal muscle, skin, anda dipose tissue. optimal cell-based therapy should i) help regain cardiac function by assisting contractile forces while not losing diastolic elasticity,i i) enhance tissue oxygen and nutrient supply as well as increase clearance of toxic metabolites, iii) limit formation of post-infarction scarring and fibrosis,a nd iv) have anti-inflammatory activity.
The amount of plasticity or transdifferentiation capacity of SSCs across av ariety of tissue lineages is under intense investigation. Whilstb one marrow serves as one source of stem cells, skeletal muscle, skin, and fat have emerged as new and putatively moreample sources at least in terms of starting material. In this aspect it must be stressed that, for transplantation purposes, acells source as closely similar as possible to the target tissue would be expected to yield the optimal results. one alternative is, of course, to transplant cells or to give such therapy that would stimulate the tissues'own stem cell proliferation, migration, and differentiation. tury with the identificationo fp roliferating cardiomyocytes( 9) leading to isolationo fam ultipotent cardiac stem cell population from an adult (10) . Immunophenotypicallyd ivergent populations of cardiac stem cells have subsequently been isolated ( 11, 12, 13, 14) . The current view also supports development of all cardiac tissues from ac ommon cellular progenitor (15) . Putatively ap ool of these multipotent progenitors would remain till adult life as ar epair reservoir (Fig.2 ) . According to the current concept the cardiac stem cells areisolated from abiopsy specimen, cultivated, and expanded in vitrob efore transplantation. Sincealready 'preprogrammed'tobe cells of the cardiac tissue, they may present am ore clear-cut differentiation pathway for cardiac therapy (16) . In the futurem aybe these cells can be directly stimulated at their niche with drugs and/or growth factors to migrate, proliferate, and differentiate to effectively repair damage after myocardial infarction (11) .
BoNe MARRoW STeM CellS
Bone marrow transplantations have been an established medical practice since 1950's with the Nobel Prize awarded to Joseph e. Murray and e. Donnall Thomas in 1990 for their discoveriesc oncerning organ and cell transplantation in the treatment of human disease. Such clinicalp ractice for treatment of hematological malignancies paved the way for the transplantation of specific subpopulations enriched and expanded in vitro. The bone marrow harbors hematopoietic (lymphoid and myeloid) and mesenchymal (colony-forming unit fibroblast,CFU-f, adherent) precursors of blood cells, and of bone, fat, cartilage, muscle, respectively (17, 18) . The transdifferentiation potential or plasticity of hematopoietic stem cells to form new cardiac muscle is under much debate. Thesecells can be isolated from abone marrow aspiratea ccording to the expression of CD34 or AC133/CD133 surface antigens (18) .
As stated, the stromal or mesenchymal stem cells of bone marrow area ble to transdifferentiate into a variety of tissue cells, including cardiomyocytes (17) . Their differentiation is strongly influenced by environmental cues. Moreover,they show high migratory capacityguided by release of chemotactic agents deriving, for example, from an acute myocardial infarct area. on the other hand, al argely passive environment such as an old infarct scar may fail to provide these cues, thus weakening the cells' therapeutic actions. The mesenchymal stem cells can be induced to differentiate into cardiomyocytes in vitro, and they readily form intercellular channels via gap junctions thusf acilitating electrical and metabolic coupling similar to cardiomyocytes (17) . However, it is difficult to evaluate whether this tendencycausing spontaneous contractions in cell cultureupon transplantation therapy translates into better cardiac performanceor increased incidence of arrhythmias.
Interestingly,t he bone marrow stem cells can be mobilized to peripheral blood with cytokines and growth factors such as G-CSF or HGF,a nd have indeed been found in increased numbers in peripheral blood after myocardial infarction (19) .
SKeleTAl MyoBlASTS AND PeRICyTeS
Adult skeletalmuscle contains 5-10% precursor cells that reside under the basementmembranes of muscle fibers (20) . They arer eadily activated in response to muscle injury to proliferate, regenerate, and heal the tissue (2). like all stem cells,a lso myoblasts require proper environmental cues for activation, proliferation, migration, and differentiation. They areeasy to isolate from askeletal muscle biopsy,can be promptly passaged and expandedinvitro. After injection to the injured myocardium, myoblasts line up with remainingc ardiomyocytes, obtain similar functional characteristics, and induce formationo fn ew vasculature ( 21) . only am inor proportion of myoblasts is able to form intercellular couplings via gap junctions (22) . As an ovel modification, myoblasts can be cultured on thermosensitive matrices to enable their transplantation as patches of continuous cell sheets (23) .
In comparison to cardiac muscle cells, satellitecells can better withstand ischemia and low levels of tissue oxygen. Together with their muscle phenotype predisposition, these facts have made the satellite cells lucrative for cell-based therapy. After almost a decade of preclinical testing,myoblasts entered clinical trials in 2000 for heart failurew ith the first promising report published by Dr Philippe Menasche and his group in 2003 (24) . Four-year follow-up data of 30 patients receiving myoblast therapyw as published in 2005 (25) showing overall safety and feasibility of this therapeutic approach.
ClINICAl exPeRIeNCe WITH STeM Cell THeRAPy
Many forms of cardiovascular disease areassociated with cardiomyocyte loss via necrosis and/or apoptosis. Myocardial infarction is the leading cause of congestive heart failurea nd death in the industrialized world. CABG operation is the standardoption to treat CABG operation is the standardoption to treat these patients,b ut not all patientsh ave sufficient amount of viable myocardium for revascularisation. Repair of heart tissue soon after ah eart attack, or regenerationo fw eakened muscle resulting from heart failureb yu sings tem cells would offer new treatment optionf or these patients. Hematopoietic stem cell (HSC) therapy for myocardial repair is limited by the number of stem cells that migrate to, engraft in, and proliferate at sites of injured myocardium. Most human studies have used transcoronary infusion of the stem cells, however,i njection of the cells directly to the myocardium by transepicardial injections or during acoronary bypass operation may be moree ffective. even intravenous administration of stem cells has been used, and in some extent stem cells have been seen to home to the site of injury (17) . Still, it is an important challenge how stem cells are efficiently delivered to target area.
INTRACoRoNARyTeCHNIqUe
Catheter-based infusion of stem cells is clinically introduced and rapidlydeveloped in patients because of the technical safety,c onvenience and mini-invasion. Several studies have been published with somewhat different settings. Transcoronary injection of autologous mononuclear stem cells to infarction related area 6days after acute myocardial infarction has been used by Strauer. Tenp atients weret reated and 10 served as controls. The cell transplantation improved left-ventricle end-systolicvolume, stroke volume index and contractility of the infarct area (26) .
In ToP-CARe-AMI study,2 0p atients with reperfused acute myocardial infarction weret reated with transcoronary transplantation of progenitorc ells either from bone marrow or from blood circulation. Both treatmentsi ncreased left ventricular ejection fraction and improved infarction related wall motion and reduced end-systolic ventricular volumes when comparedt on on-randomized matchedr eference group (27) .
In BooST-study,6 0p atients werer andomly assigned to eitherbone-marrow transplantation (n =30) or to control group (n =30). Both groups weretreated optimally after acute myocardial infarction, but the transplantation group received on the top of that autologousb one marrow transplantation. Cell transplantation did not have any adverse events, and it increased left ventricular ejection fraction (28).
Chen et al described intracoronary delivery of bone marrow-derived mesenchymal cells in 34 patients (48−60 billion cells/patient), whereas 35 control patients underwent a bone marrow harvest but received only saline infusion. Mesenchymal cell infusion resulted in increased fluoro-deoxyglucose uptake, improved wall motion, reduced ventricular dilation and anet increase of 14% in ejection fraction versus controls (29) .
They continued studies with bone marrow mesenchymal stem celltherapy in chronic cardiomyopathy. They revealed that stem cells improve clinical outcomes in patients with severei schemic cardiomyopathy, but yet the role of bonemarrow mesenchymal stem cells is not well understood. Twenty-two patients received an implantation of autologous bone marrow mesenchymals tem cell therapy; another 23 patients werep laced in ac ontrol group after percutaneous coronary intervention (PCI) of the chronically occluded left anterior descending artery. Reversible defect in the cell therapy group decreased from 16 +/-8% at baseline to 6+/-2% at 12 months (p < 0.05), and this improvement was maintained throughout the entirefollow-up period. Compared to the control group the level of exercise tolerance improved significantly 3m onths after cell therapy.T he NYHA function class also improved in the cell therapy group (2.7 +/-0.8 at baseline vs. 1.6 +/-0.1 at 3months; p< 0.05). PCI alone did not increase left ventricular ejection fraction (lVeF), but following stem cell therapy, the LVEF increased significantly from 26 +/-6% at baseline to 37 +/-9% at 3months (p <0.05) (30) .
Janssens et al. (31) conducted arandomized, double-blind placebo-controlled studyw ith 67 patients. 1d ay after as uccesful percutaneous coronary intervention for acute ST-elevation infarction, bone marrows wereharvested and patients wererandomized to receive autologous bone marrow -derived stem cells (BMSC) or placebo injectedpercutanously in the coronary arteries. optimal medical treatmentsw ere assigned in bothg roups.l eft ventricular ejection fraction assessed by MRI at 4months after the treatment was the primaryendpoint,secondary endpoints being infarct size and regional left ventricular motion. Therew as no significant improvement in the ejection fraction, but infarct size reducedinthe treatment group. Additionally,r egional systolic function was improved in the treatment group. In this study researchers concluded that BMSC transfer could favourably affect infarct remodelling.
Schächinger et al (32) conducted am ulti-center study of randomly assigned 204patients with acute myocardial infarction, who receiveda ni ntracoronary infusion of bone marrow -derived stem cells (BMSC) or placebo3to7days after successful reperfusion therapy.T his study is referred as RePAIR-AMI. left ventricular ejection fraction (lVeF) was measuredb yv entriculography.L VEF was significantly improved in the treatment group 5.5 ±7.3 comparedt ot he control group 3.0 ±6.5 (p =0.01). Also, at one year the BMSC infusionwas associated with reduced mortality,r ecurrence of myocardial infarction and any revascularization procedurecompared to the control group (p =0.01). This is the largest material published so far,and it warranted large scale studies to examinethe potential effects of progenitor cell administrationo nm ortalitya nd morbidity.
Assmus et al (33) reported a three phasecontrolled crossoverstudy named TOPCARE-CHD. In the first or pilot phase, 17 patients received progenitor cells from bone marrow (n =7)orprogenitor cells from the circulatingb lood (CBC). In the second phase 75 patients werer andomized to receive BMSC, CPC or placebo. In the thirdphase, the patients in the control group werer andomly assigned to receive BMSC or CPC and the patientswho previously received BMSC of CBC, werecrossed over to receive CPC or BMSC , respectively,a tt hree months' follow up. left ventriculographies wereo btained at 3m onths. The pa- The use of the coronary venous systemhas now been reported for the regional delivery of drugs, cells and genes to protect and/orr egenerate the myocardium (34) . Brasselet et al. described am ethod in experimental animals,w herec oronary sinus and anterior interventricular coronary vein werea ccessed using conventional over-the-wiretechnique with tipped phase-array ultrasound probe for guidance of catheter and an extendable 24-gauge nitinol needle for puncture ( 35) . Simianik reported ten patients who received skeletal myoblast transplantations via sinus coronarius to access the myocardium. Their data suggest the feasibility and procedural safety of myoblast transplantation performed via the transcoronary-venous approach using the TransAccess catheter system (36) .
Myoblast and bone marrow mononuclear cells (BMMNC) transplantation in the heart failure

PeRCUTANoUS TRANSeNDoCARDIAl INJeCTIoN
Perin et coworkers injected bone marrow cells by transendocardial catheter to 14 consecutive patients with severechronic ischemic heart failure. Seven patients serveda sc ontrols. Transplantation improved globalleftventricular ejectionfraction (37) .Inapilot study,a utologous skeletal myoblasts (196 +/-105 million cells) weret ransendocardially injected into the infarcted area in 5p atients. All cell transplantation procedures wereuneventful, and no serious adverse events occurred during follow-up. The lV ejection fractioni ncreased from 36 +/-11%t o4 1+/-9% (3 months, p=0.009) and 45 +/-8% (6 months, p=0.23) (38) . Administration of cells under MRguided minimally invasive catheter-based procedures may open up new avenues.
BoNe MARRoW Cell MoBIlIZATIoN
Granulocyte colony-stimulating factor treatment after PCI in subacute STeMI was feasible and relatively safe. Granulocyte colony-stimulating factor (G-CSF) resulted in improved myocardial perfusion of the infarcted area, which may reflect enhanced neovascularization (39) . The role of G-CSF in bone-marrow cell mobilization removes the need for bone-marrow aspiration and repeated invasive procedures. However,patients do not benefit from G-CSF when PCI is performed late. To alleviate this limitation, astrategy using ab ispecific antibody (BiAb) could target hu-man stemc ells specifically to injured myocardium and preserve myocardial function has been experimentally used (40) .
TRANSePICARDIAlINJeCTIoN TeCHNIqUe
In early studies on animals, direct intramyocardial injection of stem cells after thoracotomy was the predominant transplantation route. Transepicardial method is safe, and in humans most accurate. local environment in infarct-borderline area may naturally favour stem cell differentiation into neovascular and myocardial tissue. In the infarct area itself the milieu may need to be modified, perhaps by using different cell types, gene therapy,and growth factors. During the operation the pathologicalanatomy and the function of the heart can easilybeobserved and stem cell injection into the myocardium, whereitisthinned or therei ss car,o rw hen borderline area is targeted, is very definitive. The epicardial injection does not interferewith coronary artery or graft blood flow which is at least theoretically possible with transcoronary or graft injection. This is important when operating the patients with poor left ventricular function. Stamm and coworkers (41) injectedstem cells in a coronary bypass operation, (altogether 40 patients with either CABG with cell therapy or CABG alone). Bone marrow was harvested from the iliac crest one day beforesurgery,and purified CD133+ progenitor cells werei njected in the infarct border zone during the CABG procedure. They found out that lVeF was significantly highera t6m onths in the group with CABG and cell therapy than in the CABG-only group. Similarly,perfusion of the infarcted myocardium improved moreinpatients treated with CABG and cell therapy than in those treated with CABG alone (41) .
Dib and coworkers (25) ) transplanted autologous skeletal myoblasts concurrent with CABG or lVAD implantation in thirtyp atients. In this nonrandomized study twenty-four patients with ahistory of previous myocardial infarction and al eft ventricular ejection fraction< 40% weree nrolled in the CABG arm. In as econd arm, 6p atients underwent lVAD implantation as abridge to heart transplantation, and patients donated their explanted native hearts for testingatthe timeofheart transplantation. Myoblasts weresuccessfully transplanted in all patients without any acute injection-related complications or significant long-term, unexpected adverse events. Followup positron emission tomography scans showed new areas of glucose uptake within the infarct scar in CABG patients. echocardiography measured an average change in left ventricular ejection fraction from 28% to 35% at 1y ear and of 36% at 2y ears. Histological evaluation in 4o f6p atients who underwent heart transplantation documented survival and engraftment of the skeletal myoblasts within the infarcted myocardium (25) .
Menasche (24) injected autologous skeletal myoblasts during ac oronaryb ypass operation. local myocardial contraction improved, however 4o ft he 10 patientsn eeded defibrillator implantation (24) . With other investigators he has made the following conclusions: with respect to other types of autologous stem cells, work using the skeletal myoblast should be recognised. After adecade of work, robust experimental studies have consistently shown, in small and large animal models of myocardial infarction, that in-scar transplantation of skeletalm yoblasts resulted in their differentiation in myotubes and improved left ventricular function. The early phase I trials have clearlys hown the feasibility of the technique and revealed ap otential risk of arrhythmias. The intrinsic arrhythmogenic natureo ft he target scars makes it difficult to establish conclusively a cause-and-effect relationship between these events and myoblast engraftment. Alarge multi-centre, randomized, placebo-controlled, double-blind study (MAGIC) is currently under way and its results should clarify the pendingsafety and efficacy issues associated with skeletal myoblasts. Parallel bench work is optimizing the benefits of the procedure, primarily through the enhancement of cell survivalfollowing transplantation (42) .
In Helsinki, we have started the stem cell transplantation protocol with CABG patients. our CAD patients arec arefully examined and selected on the basis of magnetic resonance imaging (MRI),u ltrasound (US), single-photon emission computed tomography( SPeCT) and positrone mision tomography (PeT) to reveal the ischemic, hypokinetic, and akinetic areas. In the study group, the ejection fraction of the left ventricle shouldb eb elow normal despite the optimal medical treatment.Atthe beginning of operation bone marrow aspirate (30 ml) will be harvested from the iliac crest under generalanaesthesia. The samplew ill be filtered and density gradient centrifuged in order to deplete erythrocytes and platelets,a ccording to standardm ethodso ft rans-plantation laboratory of The Meilahti Hospital. A standardc oronary artery bypassg rafting is performed during cardiopulmonary bypass (CPB). Myocardial preservation is provided by antegrade cold blood cardioplegic arrest. The use of grafts( internal mammary arteries, radialarteries, vena saphena magnae) is dependent of the patient: available suitable grafts, degree of the stenosis and age. At the end of ischemia (aortic crossclamping), the final sample (6ml) of bone marrowderived mononuclearc ells is injected with transmyocardial injections, 0.2ml/injection 15 to 20 times in the scar/hibernating area of myocardium during the CABG. Tissue glue is usedto cover the injection sites to prevent the backflow of the injected material from myocardium when the heart starts beating (Fig. 3) . In randomized,double blinded fashion half of the patients receive the patient's own plasma instead of stem cell injection. At this time the method has shown to be safe. None of the patients have any adverse effects, low-output syndromes or any major complications. Unfortunately we aren ot yet ready to open the randomizing key.
Intramyocardial bonem arrow cell injection together with coronary artery bypass grafting (CABG) may offern ovelt herapeutic options for chronic ischemic heart disease. Until so far,i ntramyocardial injection has been found superior to intracoronary and retrograde coronary sinus delivery (43) .
CoNClUSIoNS
Autologous cell therapy using myoblasts or bone marrow stem cells has been shown to be asafe addition to the treatmentr egimen of cardiac failure. Cell therapy providesd amaged tissue with regenerating stimulifor the development of new muscle and vasculature,a sw ell as provides functional benefits. In the future, deeper insight into the molecular mechanisms involved in the therapeutic effects will lead to the development of morespecific applications of cell population isolations,enrichment, or expansion. For added benefit cell modifications in vitrohave shown to substantially increase the production of therapeutic mediators (44, 45) . Moreover,t he cells cultivated in vitroare feasible gene therapy vehicles in terms of controlling the expression of therapeutic genes before transplantation, andminimizing viral vectorloads to the patient.
Despite the intracoronary injections of stem cells have shown positive results in cardiac surgery patients the best way to give the cell therapy aredirect intramyocardial injections using epicardial technique. Transplantation of autologous bone marrow cells in the infarct border zone can be safely performed with this technique. Therei sn od oubt that the ultimate success or failureofcell therapy will rest on its ability to show clinical efficacy rathert han on the imputed mechanism. The initial experience with bone marrow stem cell transplantation supports idea for cardiac stem cell therapies in future. We hope that well done randomized placebo-controlled studies will be published in next few years. 
